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Abstract
Background: Macrocephaly, which is defined as a head circumference greater than or equal to + 2 standard deviations,
is a feature commonly observed in children with developmental delay and/or autism spectrum disorder. Although PTEN is
a well-known gene identified in patients with this syndromic presentation, other genes in the PI3K-AKT-mTOR signalling
pathway have also recently been suggested to have important roles. The aim of this study is to characterise the mutation
spectrum of this group of patients.
Methods: We performed whole-exome sequencing of 21 patients with macrocephaly and developmental delay/autism
spectrum disorder. Sources of genomic DNA included blood, buccal mucosa and saliva. Germline mutations were validated
by Sanger sequencing, whereas somatic mutations were validated by droplet digital PCR.
Results: We identified ten pathogenic/likely pathogenic mutations in PTEN (n = 4), PIK3CA (n = 3), MTOR (n = 1) and
PPP2R5D (n = 2) in ten patients. An additional PTEN mutation, which was classified as variant of unknown significance,
was identified in a patient with a pathogenic PTEN mutation, making him harbour bi-allelic germline PTEN mutations.
Two patients harboured somatic PIK3CA mutations, and the level of somatic mosaicism in blood DNA was low. Patients
who tested positive for mutations in the PI3K-AKT-mTOR pathway had a lower developmental quotient than the rest of
the cohort (DQ = 62.8 vs. 76.1, p = 0.021). Their dysmorphic features were non-specific, except for macrocephaly.
Among the ten patients with identified mutations, brain magnetic resonance imaging was performed in nine, all of
whom showed megalencephaly.
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Conclusion: We identified mutations in the PI3K-AKT-mTOR signalling pathway in nearly half of our patients
with macrocephaly and developmental delay/autism spectrum disorder. These patients have subtle
dysmorphic features and mild developmental issues. Clinically, patients with germline mutations are difficult
to distinguish from patients with somatic mutations, and therefore, sequencing of buccal or saliva DNA is
important to identify somatic mosaicism. Given the high diagnostic yield and the management implications,
we suggest implementing comprehensive genetic testing in the PI3K-AKT-mTOR pathway in the clinical
evaluation of patients with macrocephaly and developmental delay and/or autism spectrum disorder.
Keywords: Somatic mosaicism, Macrocephaly, Megalencephaly, Developmental delay, Autism spectrum
disorder, PTEN, MTOR, PIK3CA, PPP2R5D
Background
Macrocephaly is defined as a disproportionally enlarged
head size with an occipitofrontal circumference greater
than or equal to +2 standard deviations (SDs). On the
other hand, megalencephaly is defined as hyperplasia of
the brain parenchyma observed in a radiological examin-
ation together with clinical features of macrocephaly.
Both conditions are associated with developmental delay
(DD) and/or autism spectrum disorder (ASD). Moreover,
a recent neuroimaging study has shown that brain vol-
ume overgrowth is linked to the emergence and severity
of autistic social deficits [1].
ASD is a complex, behaviourally defined disorder char-
acterised by impairments in communication and recip-
rocal social interaction, restrictive interests and
repetitive stereotypic behaviours [2]. It is known that
ASD has a strong genetic basis [3, 4], and environmental
factors might also influence the development of ASD
[5–7]. Previous studies have reported a genetic diagnosis
in 10% to 40% of patients with ASD [8–11]. According
to the American Academy of Pediatrics guidelines for
ASD published in 2000, genetic testing is a standard
diagnostic test for children with ASD and dysmorphic
features or intellectual disability (ID).
As shown in previous studies, 14–34% of children with
ASD also have macrocephaly [12–17], and a meta-
analysis revealed that 15.7% have macrocephaly and
9.1% have brain overgrowth [18]. PTEN is a well-known
gene associated with ASD and macrocephaly [19–21].
Hence, genetic testing for PTEN mutations is recom-
mended as part of the clinical evaluation in this group of
patients [22–24]. Recently, mutations in other genes in
the PI3K-AKT-mTOR signalling pathway, including
PIK3CA, PIK3R2, MTOR, CCND2 and PPP2R5D, were
also reported in patients with ASD/DD and macroceph-
aly [25–30]. Although most PTEN mutations reported in
this group of patients were germline mutations [20, 31],
mutations in other genes in the PI3K-AKT-mTOR sig-
nalling pathway were frequently detected with a low
level of mosaicism, which are undetectable using
conventional Sanger sequencing. The use of next-
generation sequencing, such as whole-exome sequencing
(WES) or target panel sequencing, enables the detection
of the low level of mosaicism in these patients. In this
study, we aim to define the mutation spectrum in a co-
hort of patients with ASD/DD and macrocephaly using
WES.
Methods
Patient recruitment
We recruited patients from January 2013 to December
2016 at the Duchess of Kent Children’s Hospital Child
Assessment Center (DKCAC). Patients were initially
assessed by a developmental paediatrician and relevant
allied health professionals, including clinical psycholo-
gists, physiotherapists, occupational therapists and
speech therapists. The developmental profile of patients
less than 72 months of age was assessed using the
Griffiths Mental Developmental Scales-Extended Revised
(GMDS-ER). The developmental quotient (DQ) score
was calculated based on the neurodevelopmental assess-
ment to compare the developmental profiles between
mutation-positive and mutation-negative patients. Be-
cause many patients were examined using more than
one developmental assessment, the DQ scores from the
first assessment were used. DQ scores were estimated
for four patients based on their allied health assessment
records and a clinical assessment by a developmental
paediatrician because the patient was either too sick for
the formal assessment with GMDS-ER (patient 3) or
data were missing (patients 5, 15 and 19). Intellectual
functioning of children ≥72 months of age was assessed
using the Hong Kong Wechsler Intelligence Scale. ASD
was diagnosed based on the Diagnostic and Statistical
Manual of Mental Disorders—Fourth Edition (DSM-IV)
criteria for ASD. Suspected cases were further assessed
using the Autism Diagnostic Observation schedule
(ADOS).
Developmental paediatricians at DKCAC referred pa-
tients with negative findings in the chromosomal
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microarray to the clinical geneticist when the patients
also presented with macrocephaly (head circumference
≥ + 2 SD). These patients were recruited by the clinical
geneticist, with the exception of patients presenting with
obvious syndromic diseases who were assessed using tar-
geted genetic tests and excluded from this study.
Twenty-one unrelated patients were recruited in this
study. Anthropometric data used for the measurements
are specific to Hong Kong. Buccal swab or saliva sample
was obtained in addition to the blood sample from five
patients. This study was approved by the Institutional
Review Board of the University of Hong Kong/Hospital
Authority Hong Kong West Cluster (UW 12–211), and
written consent was obtained from the patients’ parents.
WES
WES was first performed at Macrogen Inc. and then at
our university at a later stage of the project using either
a TruSeq Exome Enrichment Kit (n = 9), SeqCap EZ Ex-
ome + UTR Exome Kit (n = 9) or TruSeq Rapid Exome
Library Prep Kit (n = 3). The choice of the enrichment
kit depended on the library preparation kit available at
the time of sequencing. We aimed to obtain a minimum
of 50X depth for WES performed with genomic DNA
obtained from the blood and a minimum of 100X depth
for WES performed with DNA derived from buccal mu-
cosa or saliva samples. The increased sequencing depth
in buccal and saliva samples served to increase the
chance of detecting somatic mutations. Details of the li-
brary preparation method, sequencer used and average
depth after sequence alignment of each individual is pre-
sented in Additional file 1.
Variant calling and data analysis
Raw reads were aligned to the UCSC hg19 reference
human genome using BWA 0.5.7, and variant calling
was performed according to the best practices of
GATK 3.4. The output VCF files were than annotated
using ANNOVAR. The following criteria were applied
to filter the variants and generate a list of high-
quality variants for subsequent analyses: variants lo-
cated outside the exonic regions and splice sites, syn-
onymous variants, population frequency ≥ 1% or total
depth < 10X. Genes involved in the PI3K-AKT-mTOR
signalling pathway (PTEN, AKT1, AKT3, PIK3CA,
MTOR, PIK3R2, CCND2, PPP2R5D and PPP2R1A)
were prioritised for analysis because of their known
pathogenicity in patients with macrocephaly and DD/
ASD, and other genes in the PI3K-AKT signalling
pathway obtained from Kyoto Encylopedia of Genes
and Genomes (KEGG; reference: hsa04151) were also
analysed. Mutations identified in this pathway that are
associated with diseases are expected to be rare, and
activating mutations are likely to be found in the
Catalogue of Somatic Mutations in Cancer (COSMIC)
database [27, 32]. In addition, genes involved in epi-
genetic regulation have recently been reported to be
an important cause of macrocephaly/overgrowth and
DD/ASD, and thus, genes related to epigenetic regula-
tion (CHD8, DNMT3A, EED, EZH2, HIST1H1E and
NSD1) were also prioritised for analysis [33].
Confirmation of variants
For germline mutations, variants were confirmed by
Sanger sequencing, and parental sequencing was also
performed to determine whether the mutation was de
novo or inherited. For somatic mosaic mutations,
droplet digital PCR was used for validation, as de-
scribed previously [32].
Statistical analysis
Unpaired t tests were performed to assess the signifi-
cance between the DQ scores of patients with and with-
out mutations. A p-value < 0.05 was considered
statistically significant. Analyses were performed using
SPSS Statistics version 19 (IBM).
Results
Twenty-one patients (17 males and 4 females, 4 to
108 months of age at the time of clinical assessment/
recruitment) with macrocephaly and DD/ID/ASD
were recruited. All patients had DD at the time of re-
cruitment, and three patients were diagnosed with ID
in subsequent assessments. Among the 21 patients,
ten were also diagnosed with ASD and two with sus-
pected ASD (i.e., patients with autistic features who
had not yet satisfied all the DSM-IV criteria for a
diagnosis of ASD). A summary of the patients’ clinical
presentations is presented in Table 1. Prior to WES,
the chromosomal microarray was performed on these
patients, as described previously [34], and no patho-
genic/likely pathogenic copy number variations were
identified in these patients. WES identified ten patho-
genic/likely pathogenic mutations in ten patients (Fig.
1, Table 2), corresponding to a diagnostic yield of
47.6%. All pathogenic mutations were located in
genes involved in the PI3K-AKT-mTOR signalling
pathway, including PTEN (n = 4), PIK3CA (n = 3),
MTOR (n = 1) and PPP2R5D (n = 2). Although most
variants were germline mutations, two somatic
PIK3CA mutations were identified. No pathogenic
mutations were identified in genes related to epigen-
etic regulation, such as CHD8, DNMT3A, EED and
NSD1, as reported by Tatton-Brown K et al. [33], and
the analysis of the remainder of the exome did not
reveal other variants of interest.
Mutations in the PTEN gene were the most frequently
identified mutations in our patients, with four
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pathogenic variants found in four patients (19% among
21 patients). Both missense and frameshift mutations
were identified. Although the PTEN p.(Ser170Thr) mu-
tation detected in patient 4 has not previously been re-
ported, a mutation in the same codon, resulting in
PTEN p.(Ser170Arg), has been reported in multiple pa-
tients with PTEN cancer syndrome [35, 36], suggesting
the pathogenicity of mutations in this amino acid. The
mutation in patient 6 was a frameshift mutation and
therefore a pathogenic mutation, because loss of
Table 1 Clinical presentations of all patients recruited in this study
Patient
ID
Sex First
assessment
(years)
Most recent
assessment
(years)
HC (z-score) DQ ASD Developmental
problem(s)
Other clinical
features
MRI findings Gene
1 M 3.0 5.2 3.6 75 Mild GDD with
severe language
delay
2/3/4 syndactyly MEG, PG, VM, PWMSA PIK3CA
2 M 1.5 4.1 3.2 55 Moderate GDD Mild 2/3 syndactyly MEG, PG, PWMSA PIK3CA
3 M 0.8 1.6 5.9 50* Moderate GDD Recurrent
respiratory
infections,
hypoglycaemia
MEG, PG, VM, PWMSA PTEN
4 M 2.3 6.5 4.0 73 Suspected
ASD
Mild GDD NA MEG, PG, PWMSA PTEN
5 M 0.4 0.7 6.7 62* Mild GDD Liver
haemangioma
MEG, PG, VM, PWMSA MTOR
6 M 2.7 8.2 4.5 80 ASD Mild GDD 2/3 syndactyly NA PTEN
7 M 2.0 11.6 2.6 49 ASD Moderate GDD,
mild ID
Hypertelorism,
epilepsya
MEG PPP2R5D
8 M 1.8 5.3 2.2 54 Suspected
ASD
Moderate GDD,
mild ID
Hypertelorism,
epilepsyb
MEG PPP2R5D
9 M 2.0 3.5 3.5 62 ASD Mild GDD with
moderate
language delay
Left lower limb
hypertrophy with
2/3 syndactyly
MEG PIK3CA
10 M 2.6 6.0 3.4 68 Mild GDD Frontal bossing MEG PTEN
11 M 4.4 10.1 3.4 95 ASD Language delay z-scores for height:
3.0; weight: 5.6
Normal Negative
12 M 2.3 6.3 3.3 79 ASD Borderline delay
with language
delay
Left ptosis, scoliosis Dilated cisterna magna,
relative atrophy of the
right cerebellar hemisphere
Negative
13 F 9.8 10.3 3.1 NA ASD NA Normal Negative
14 F 1.6 7.3 3.3 75 Borderline delay
with language
delay
Intra-cranial
haemorrhage in
the perinatal
period
Aqueduct stenosis with
hydrocephalus
Negative
15 F 4.0 6.0 4.2 90* ASD Language delay NA NA Negative
16 M 2.2 23.4 3.2 71 ASD Borderline delay NA NA Negative
17 M 1.8 14.4 4.8 84 ASD Borderline delay Epilepsyc Normal Negative
18 F 2.4 6.2 2.2 78 Borderline delay NA NA Negative
19 M 2.0 19.8 2.1 50* ASD Moderate GDD,
moderate ID
Epilepsyd NA Negative
20 M 2.0 2.3 2.8 67 Mild GDD NA Dilated ventricles with
external hydrocephalus
Negative
21 M 2.4 10.8 3.0 72 Mild GDD Cleft lip and palate,
nasal deformity
Normal Negative
*Estimated DQ scores
aEpilepsy: onset at 4 years of age, generalised tonic-clonic seizure
bEpilepsy: onset at 4 days of age, generalised epileptic spasm
cEpilepsy: onset at 11 months, focal seizure with impaired awareness
dEpilepsy: onset 11 years of age, generalised tonic-clonic seizure
MEG megalencephaly, PG polymicrogyria, VM ventriculomegaly, PWMSA periventricular white matter signal abnormalities, NA not available
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function mutations is known to cause disease. The
PTEN p.(Tyr68Cys) mutation identified in patient 10 has
already been reported in multiple patients with Cowden
Syndrome [37, 38].
In addition, we report here a second patient with bi-
allelic germline PTEN mutations. Two PTEN mutations
were identified in patient 3, where p.(Cys105Phe) was a
de novo mutation and p.(Lys164Asn) was maternally
inherited. Based on the sequencing data, the two muta-
tions did not occur in the same allele (Additional file 2,
Fig. S1a). Exon 5 was cloned to confirm that the muta-
tions were located on different alleles, and clonal se-
quencing showed that the two mutations occurred on
different alleles (Additional file 2, Fig. S1b). The muta-
tion p.(Cys105Phe) has not been reported, but a muta-
tion in the same codon resulting in p.(Cys105Tyr) has
been reported in patients with Bannayan-Riley-
Ruvalcaba Syndrome [39], suggesting the pathogenicity
of mutations in this amino acid. The maternally inher-
ited p.(Lys164Asn) mutation has not been reported in a
disease-specific database and has only been reported in
the Exome Aggregation Consortium (ExAC) database
with an allelic frequency of 1 in 120,466. Familial test-
ing showed that this mutation was also detected in the
patient’s mother and elder sister, and both the mother
and elder sister had macrocephaly (z-scores for the
head circumference were 2.6 and 3.7, respectively).
Both had unremarkable developmental issues. Active
cancer surveillance was recommended, and at the age
of 38, the patient’s mother was diagnosed with multi-
focal papillary carcinoma. Based on the above evidence,
although the variant p.(Lys164Asn) being pathogenic
was compelling, it was still classified as a variant of un-
known significance. It was because the mother did not
meet the diagnostic criteria for PTEN hamartoma
tumour syndrome, who only fulfilled one major criter-
ion (macrocephaly) and one minor criterion (papillary
carcinoma) [40]. Patient 3 who had bi-allelic mutations,
however, displayed a severe clinical presentation des-
pite one of the mutation being classified as a variant of
unknown significance. In addition to megalencephaly,
polymicrogyria and developmental delay, he suffered
from recurrent sinopulmonary infections and colitis,
resulting in persistent fever and septic shock that re-
quired care in the intensive care unit. The immune
workup showed hypogammaglobulinaemia, specifically,
a low level of IgG subclass 3. During a salmonella
gastrointestinal infection at 19 months of age, a dihy-
drorhodamine test showed a suppressed oxidative burst
with only half of the function compared to the control.
However, a specific primary immunodeficiency syn-
drome was not identified. Second, this patient had suf-
fered from recurrent hypoglycaemia since 19 months
of age that required high glucose infusions; however,
his insulin level was normal and an extensive endocrine
workup was unremarkable. The patient died at
25 months of age due to sepsis. This case showed that
patients with bi-allelic PTEN mutations can present
with other PI3K-AKT-mTOR pathway-related features,
including the recurrent respiratory infections observed
in patients with PIK3CD mutations [41, 42] and
hypoglycaemia observed in patients with AKT2 or
AKT3 mutations [43, 44].
The PIK3CA mutation was the second most common
mutation identified in our patients (patients 1, 2 and 9).
The germline mutation in patient 2 was inherited from
his mother, who had macrocephaly (z-score of head
circumference was 4.6) but no history of developmental
issues. In addition to the germline mutation, two
somatic mutations were identified, and all mutations
Table 2 Mutations in genes involved in the PI3K-AKT-mTOR pathway identified in the ten patients with macrocephaly and DD/ASD
Patient
ID
Gene Nucleotide
change
Amino acid change Inheritance Mutation
type
Allelic count in
ExAC
No. of cases in
COSMIC
Reported
mutation
1 PIK3CA c.G263A p.(Arg88Gln) De novo Mosaic 0 137 43
2 PIK3CA c.G1030A p.(Val344Met) Maternal Germline 0 15 27
3 PTEN c.G314T p.(Cys105Phe) De novo Germline 0 6 39b
c.G492T p.(Lys164Asn) Maternal Germline 1 in 120,466 0b
4 PTEN c.G509C p.(Ser170Thr) De novo Germline 0 0b 35.36b
5a MTOR c.G5395A p.(Glu1799Lys) De novo Germline 0 10 28.45
6 PTEN c.546delA p.(Lys183ArgfsTer16) De novo Germline 0 0b
7 PPP2R5D c.G592A p.(Glu198Lys) De novo Germline 0 1 29.46
8 PPP2R5D c.G592A p.(Glu198Lys) De novo Germline 0 1 29.46
9 PIK3CA c.G2740A p.(Gly914Arg) De novo Mosaic 0 2 25.27
10 PTEN c.A203G p.(Tyr68Cys) De novo Germline 0 4 37.38
The COSMIC database (June 2017) was accessed to retrieve the number of somatic mutations identified in cancer samples
aThis patient was reported in a previous study [28] with the patient ID LR15-065
bOther mutations in the same codon have been reported
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have been reported previously [25, 27]. WES detected a
p.(Arg88Gln) mutation in patient 1, with a percentage
of 4.5% (4 of 89 reads) in the blood and 27.1% (29 of
107 reads) in the buccal mucosa, whereas confirmation
using droplet digital PCR showed that the percentages
of p.(Arg88Gln) mutations in the blood and buccal
mucosa samples were 8.6 and 22.8%, respectively. For
patient 9, WES detected a p.(Gly914Arg) mutation with
a percentage of 2.8% (3 of 109 reads) in the blood and
11.9% (13 of 109 reads) in the saliva. Again, droplet
digital PCR confirmed the WES results, showing that
the percentages of mutations were 2.6, 9.3 and 22.8% in
the blood, saliva and buccal mucosa samples from
patient 9, respectively. Our results confirmed previous
findings that the mutation load in saliva or buccal
mucosa is higher than the mutation load in the blood
[25–27].
Finally, known pathogenic variants in the MTOR [28,
45] and PPP2R5D [29, 46] genes were also identified in
our patients. Patient 5, who had a MTOR mutation, has
already been reported in another publication (referred to
as LR15-065 in the publication) describing a wide
spectrum of patients with germline/somatic MTOR
mutations [28]. In addition, PPP2R5D p.(Glu198Lys) was
identified twice in two unrelated patients as de novo
mutation. Both patients had a clinical presentation
compatible with other patients with PPP2R5D muta-
tions, including hypertelorism, frontal bossing, and a his-
tory of epilepsy.
At the time when genetic counselling was provided to
patients with mutations, patients were re-examined to
determine whether they had features of PTEN hamar-
toma tumour syndrome [40] such as macular pigmenta-
tion of the glans penis, mucocutaneous lesions and
lipomas. For megalencephaly-capillary malformation
syndrome (MCAP)/megalencephaly-polymicrogyria-
polydactyly-hydrocephalus syndrome (MPPH) [47], fea-
tures of syndactyly, signs of overgrowth and vascular
anomalies were assessed. Most of these features were
absent in our patients. Only a small minority of pa-
tients presented with additional clinical features, such
as syndactyly, hypertelorism and epilepsy. Our findings
demonstrated the diversity of the clinical spectrum in
this group of patients (see Table 1). Overall, patients
with identified mutations had only subtle dysmorphic
features (Fig 1). The mean DQ scores for mutation-
positive and mutation-negative patients were 62.8 and
76.1, respectively, and the difference was statistically
significant (p = 0.021). The prevalence of ASD/autistic
features was similar between the two groups. It was
noted that except for the two patients with PPP2R5D
mutations, the head circumference of other mutation-
positive patients were > + 3 SD. However, patients who
tested positive for mutations in the PI3K-AKT-mTOR
pathway did not had a significant difference in head cir-
cumference than mutation-negative patients. We also
reviewed the brain magnetic resonance imaging (MRI)
findings. Of the ten patients with an identified muta-
tion, nine underwent MRI (Fig. 2). Megalencephaly was
present in all nine of these patients; in addition, poly-
microgyria was also identified in five patients, periven-
tricular white matter signal abnormalities were
identified in five patients, and ventriculomegaly was
identified in three patients. With the exception of brain
overgrowth, mutation-positive patients had no struc-
tural brain abnormalities. In contrast, three of the seven
mutation-negative patients also had brain abnormal-
ities, such as Dandy-Walker variant (n = 1) or aqueduct
stenosis with hydrocephalus (n = 2). The brain MRI
findings of the remaining four patients were normal.
Discussion
In this study, we aimed to characterise the mutation
spectrum of patients with macrocephaly and DD/ASD.
Among the 21 patients, ten had mutations in the PI3K-
AKT-mTOR signalling pathway, indicating the
importance of this pathway in macrocephaly with DD/
ASD (Table 2). Our overall diagnostic yield was 47.6%,
and PTEN mutations were detected in 19% of patients
(n = 4), similar to previous studies detecting PTEN
mutations/deletions in patients with DD/ASD [20, 21,
48, 49]. The higher diagnostic yield in this study is be-
cause multiple genes in the PI3K-AKT-mTOR pathway
in addition to PTEN were considered, and in selected
patients, WES of reasonably high depth was performed
using additional sources of DNA, including saliva or
buccal mucosa samples, rather than blood samples
alone. Findings from our study suggest the need to re-
fine the recommendation of current guidelines for the
genetic evaluation of patients with macrocephaly and
DD/ID/ASD. The American Academy of Pediatrics
guidelines do not specifically mention an evaluation of
children with macrocephaly and DD/ID [50], but the
ASD evaluation proposed by the Autism Consortium
Clinical Genetics/DNA Diagnostics Collaboration [22],
the American College of Medical Genetics and Genom-
ics [23] and other experts [24] only suggests genetic
testing for PTEN mutations. From a practical perspec-
tive, children with DD/ASD will be referred for genetic
consultation when their developmental problem is
moderate to severe or when they present with dys-
morphic features. However, based on our findings, most
patients with mutations present with mild to moderate
developmental problems, and dysmorphism is mild and
non-specific. The absence of typical features of PTEN
hamartoma tumour syndrome (such as glans penis pig-
mentation, mucocutaneous lesions and lipomas) may
be due to the relatively young age of the patients or to
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the variable presentation of these features. Thus, gen-
etic tests should be considered for patients with DD/
ASD and macrocephaly, regardless of the degree of
DD/ASD and the presence/absence of dysmorphic fea-
tures. A panel of genes in the PI3K-AKT-mTOR path-
way, including but not limited to PTEN, should be
tested, and a low level of mosaicism for variants should
be considered when collecting samples from patients
for DNA extraction and determining the methodology
to use to detect mutations [25–28]. Additional sources
of DNA obtained from the buccal mucosa, saliva or
brain (if available) should also be used for sequencing,
and next-generation sequencing with reasonably high
depth and coverage of genes in the PI3K-AKT-mTOR
pathway should be performed. Although our use of
WES successfully identified somatic mutations in two
patients, a targeted gene panel has the advantage of
higher depth than WES and therefore is a better choice
for testing.
The genetic diagnosis of mutations in genes involved
in the PI3K-AKT-mTOR pathway is clinically important.
First, monogenic mutations in the PI3K-AKT-mTOR
Fig. 1 Clinical photographs of patients with mutations in the PI3K-AKT-mTOR pathway. Clinical photographs of patients with mutations identified
in the PI3K-AKT-mTOR pathway are shown. For patient 1, syndactyly is shown. Patient 7 presented with hypertelorism and frontal bossing
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pathway are important in the pathogenesis of a subset of
patients with DD/ASD. The genetic information may fa-
cilitate genetic counselling and estimate the risk of oc-
currence. Second, the genetic diagnosis facilitates a
determination of prognosis. For example, patients with
PPP2R5D mutations are expected to have poor language
and locomotor performance, moderate to severe ID/DD
and epilepsy [29, 46]. Third, Riviere et al. recommended
that brain MRI should be performed on these children,
with special attention to abnormal patterns of headache,
changes in gait or other neurological problems [25].
Fourth, long-term cancer surveillance should be pro-
vided for these patients, because the PI3K-AKT-mTOR
pathway is an important cancer-related pathway and is
Fig. 2 MRI of patients with mutations in the PI3K-AKT-mTOR pathway. a MRI in patients 1–5 showing megalencephaly, polymicrogyria and periventricular
white matter signal abnormalities. Ventriculomegaly was observed in patients 1, 3 and 5. b MRI in patients 7–10 showing megalencephaly, without other
abnormalities. MRI was not available for patient 6 because the family declined the MRI
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frequently mutated in tumours [51]. Patients with PTEN
mutations have an increased risk of breast cancer, thy-
roid cancer, melanoma and endometrial cancer [52, 53],
and recently, Peterman et al. found that patients with
somatic PIK3CA mutations had an increased risk of
Wilms tumour [54]. Finally, genetic counselling and
family cascade testing should be provided to patients
with germline mutations, because mutations may have
been inherited from parents with macrocephaly yet with-
out a remarkable history of DD/ID. One of the PTEN
mutations in patient 3 was maternally inherited, but his
mother had a clinically unremarkable presentation, ex-
cept for macrocephaly. She was counselled, and after a
year of cancer surveillance, she was diagnosed with
early-stage thyroid cancer. This finding illustrates the
importance of family cascade testing and cancer surveil-
lance. Nevertheless, because of the complexity of genetic
tests (such as the choice of tissue and depth of sequen-
cing) and diverse clinical presentations in patients, we
emphasise that genetic testing should only be offered by
clinical geneticists who provide comprehensive pre- and
post-test counselling to ensure the quality of the test,
data interpretation and standard of care.
Here, we reported a second patient with bi-allelic
germline PTEN mutations. Although one of the muta-
tions was classified as variant of unknown signifi-
cance, his clinical presentation was more severe than
typical patients with heterozygous PTEN mutations
and siblings with homozygous mutations, as reported
by Schwerd et al. [55]. According to these authors,
the homozygous p.Leu182Ser mutation is functionally
hypomorphic, and thus, the patients have a recessive
form of macrocephaly syndrome with a milder clinical
course and lower risk of malignancy. Our patient (pa-
tient 3) serves as a contrasting example, showing that
patients with bi-allelic PTEN mutations can present
with a more severe clinical course involving multiple
systems and display early lethality.
Historically, different nomenclatures have been used in
this group of patients, including but not limited to
macrocephaly-capillary malformation [56], MCAP [25],
MPPH [25, 30], hemimegalencephaly [26], focal cortical
dysplasia [28], megalencephaly [28, 57], and PIK3CA-re-
lated overgrowth spectrum [58]. The overlapping pheno-
typic presentation makes a differential diagnosis difficult,
and the use of different nomenclatures is confusing to
clinicians and patients. For example, MCAP and MPPH
are usually associated with PIK3CA and PIK3R2
mutations, respectively. However, patients 1 and 9 in
our study, who had somatic PIK3CA mutations, did not
present with somatic features observed in MCAP other
than syndactyly [47], whereas patients 3, 4 and 5 who
did not have PIK3R2 mutations, presented with
megalencephaly, polymicrogyria or ventriculomegaly,
consistent with MPPH. Thus, a differential diagnosis is
difficult, and the clinical presentation is a spectrum. A
consensus on the nomenclature for this group of pa-
tients should be reached among international clinicians
and scientists to facilitate communication, management,
determination of prognoses, and further research and
clinical trials [58]. Although the umbrella term
“PIK3CA-related overgrowth spectrum” has been pro-
posed to encompass patients with PIK3CA mutations
[58], it is not sufficiently comprehensive to describe pa-
tients with macrocephaly who are complicated with DD/
ID/ASD, because mutations in genes other than PIK3CA
have also been identified in this group of patients. Since
these patients share overlapping phenotypes and muta-
tions in the same pathway, we propose the umbrella
term “mTOR pathway-related macrocephaly spectrum”
to encompass patients with macrocephaly and DD/ID/
ASD associated with germline or somatic mutations in
the PI3K-AKT-mTOR signalling pathway.
The limitation of the present study is that we only in-
cluded a small number of patients, and long-term follow
up was not available for all patients. In addition, the se-
quencing strategy was not uniform throughout the study
because we made changes to improve the sequencing
depth and to include DNA obtained from saliva and
buccal mucosa samples, in addition to blood samples.
We believe that brain MRI findings may be an indicator
for genetic testing because all patients with mutations in
the PI3K-AKT-mTOR pathway had features of megalen-
cephaly and/or brain overgrowth, rather than macro-
cephaly alone. Nevertheless, our findings should be
confirmed in larger studies, given our small sample size.
Because the association between the PI3K-AKT-mTOR
pathway and macrocephaly and DD/ID/ASD is relatively
new, we have limited knowledge of this disease
spectrum. We hope that the identification of more pa-
tients will enable the better characterisation of the clin-
ical presentation of this group of diseases, and hence,
clinicians will be able to provide better clinical manage-
ment for these patients.
Conclusions
In summary, nearly 50% of children with macrocephaly
and developmental delay/ASD had mutations in the
PI3K-AKT-mTOR pathway, suggesting the importance
of this pathway in this patient group. The presence of
somatic mosaicism increases the difficulty in providing a
molecular diagnosis, and therefore, DNA samples from
different tissues should be sequenced. Finally, we
propose the use of the umbrella term “mTOR pathway-
related macrocephaly spectrum” to emphasise the over-
lapping clinical phenotypes and genotypes associated
with this spectrum of patients.
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Additional files
Additional file 1: Summary of sequencing data for all patients with
macrocephaly and DD/ASD. The data consist of the sequencing
information for all patients recruited in this study, including the kit used
to prepare the library, sequencers, and the depth of coverage. (XLSX
18 kb)
Additional file 2: Bi-allelic PTEN mutations in patient 3. The file consists
of WES reads and clonal sequencing data to show that patient 3 has two
mutations in different PTEN alleles. (DOCX 936 kb)
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